NCT00064428 - OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction | Biotech Hunter

Enrollment

12,092

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions

Thromboembolism

Interventions

DRUG

fondaparinux - UFH not indicated

2.5mg od, sc (1st dose IV) x 8 days or discharge

OTHER

Control - UFH not indicated

Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge

DRUG

Fondaparinux - UFH indicated

2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion

DRUG

Control - UFH

UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge